Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MBBS, MSc, MD, Jeffrey I. Weitz, MD, Walter Ageno, Yoriko De Sanctis, MS, Wentao Lu, PhD, Jianfeng Xu, PhD, John Albanese, BS, MBA, Chiara Sugarmann, BSN, MSHS, Concetta Lipardi, MD PhD, Theodore E. Spiro, MD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 163.

https://doi.org/10.1182/blood-2019-122934

Published: 2019

Journal Articles

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Alex C. Spyropoulos, MD, Gary E. Raskob, PhD, Alexander T Cohen, MBBS, MSc, MD, Walter Ageno, Jeffrey I. Weitz, MD, Theodore E. Spiro, MD, Wentao Lu, PhD, Concetta Lipardi, MD PhD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 2441.

https://doi.org/10.1182/blood-2019-122930

Published: 2019

Journal Articles

Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial

Alex C. Spyropoulos, MD, Walter Ageno, Gregory W. Albers, MD, C. Gregory Elliott, MD, Jonathan L. Halperin, MD, William R. Hiatt, Gregory Maynard, MD, P. Gabriel Steg, MD, Jeffrey I. Weitz, MD, Theodore E. Spiro, MD, Wentao Lu, PhD, Chiara Sugarmann, BSN, MSHS, Concetta Lipardi, MD PhD, Gary E. Raskob, PhD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 3669.

https://doi.org/10.1182/blood-2019-122621

Published: 2019

Journal Articles

Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism

Blood (2018) 132 (Supplement 1): 2527.

https://doi.org/10.1182/blood-2018-99-113589

Published: 2018

Journal Articles

Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis

Jeffrey I. Weitz, MD, Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MD, Theodore E. Spiro, MD, Yoriko De Sanctis, MS, Jianfeng Xu, PhD, Eunyoung Suh, PhD, Wentao Lu, PhD, Concetta Lipardi, MDPhD, Elliot S. Barnathan, MD

Blood (2018) 132 (Supplement 1): 1236.

https://doi.org/10.1182/blood-2018-99-111911

Published: 2018

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Scott D. Berkowitz, MD, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Keith A A Fox, MBBS, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 1104.

https://doi.org/10.1182/blood.V130.Suppl_1.1104.1104

Published: 2017

Journal Articles

The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation

Xiaoyu Yan, PhD MSc, Gary Peters, MD, Amarnath Sharma, Partha Nandy, Christopher Nessel, MD, Dirk Garmann, Stefan Willmann, Anne Hermanowski-Vosatka, Alexander Solms, Scott D. Berkowitz, MD, Theodore E Spiro, MD, Keith A A Fox, MBBS, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Jonathan P Piccini, Manesh Patel, Richard C Becker, Liping Zhang

Blood (2017) 130 (Supplement 1): 1107.

https://doi.org/10.1182/blood.V130.Suppl_1.1107.1107

Published: 2017

Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

Scott D. Berkowitz, MD, Keith A A Fox, MBBS, Stephan Schmidt, Jeffrey I Weitz, MD FRCPC, FACP, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann

Blood (2017) 130 (Supplement 1): 3718.

https://doi.org/10.1182/blood.V130.Suppl_1.3718.3718

Published: 2017

Journal Articles

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Gary E. Raskob, PhD, Nick Van Es, MD, Peter Verhamme, MD PhD, Marc Carrier, MD, Marcello Di Nisio, MD, David A. Garcia, MD, Michael A. Grosso, MD, Ajay K. Kakkar, MBBS, Michael J. Kovacs, MD, Michele F. Mercuri, MD PhD FAHA, Guy Meyer, MD, Annelise Segers, MD, Minggao Shi, PhD, Tzu-Fei Wang, MD, Erik Yeo, MD FACP, FRCPC, George Zhang, PhD, Jeffrey I. Zwicker, MD, Jeffrey I. Weitz, MD, Harry R. Büller, MD PhD

Blood (2017) 130 (Supplement 1): LBA-6.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-6.LBA-6

Published: 2017

Journal Articles

Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients

Gary E Raskob, PhD, Harry Buller, MD, PhD, Pantep Angchaisuksiri, MD, Doyeun Oh, MD, PhD, Zoltan Boda, MD, PhD, DSc, Roger M. Lyons, MD, Jeffrey I. Weitz, MD, George Zhang, PhD, Hans J Lanz, MD, Michele Mercuri, MD, PhD, FAHA

Blood (2013) 122 (21): 211.

https://doi.org/10.1182/blood.V122.21.211.211

Published: 2013

Journal Articles

Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism

Giancarlo Agnelli, MD, Harry Roger Buller, MD, PhD, Alexander Cohen, MD, Madelyn Curto, DVM, Alexander S. Gallus, M.D., Margot R. Johnson, MD, BSC, Anthony R. Porcari, PhD, PharmD, Gary E Raskob, PhD, Jeffrey I. Weitz, MD

Blood (2012) 120 (21): LBA-1.

https://doi.org/10.1182/blood.V120.21.LBA-1.LBA-1

Published: 2012

Journal Articles

Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty.

Jeffrey I. Weitz, MD, FACP, FRCP, Charlie Cao, Ph.D., Bengt Eriksson, MD, William D. Fisher, MD, Stuart Kupfer, MD, Gary E Raskob, PhD, Jeffrey Spaeder, MD, Alexander GG Turpie, MD

Blood (2009) 114 (22): 170.

https://doi.org/10.1182/blood.V114.22.170.170

Published: 2009

Journal Articles

Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation

Jeffrey I. Weitz, MD, FACP, FRCP, Stuart J. Connolly, MD, FRCPC, Satoshi Kunitada, James Jin, Indravadan Patel

Blood (2008) 112 (11): 33.

https://doi.org/10.1182/blood.V112.11.33.33

Published: 2008

Journal Articles

Thrombin Aptamer HD1 Inhibits Prothrombin Activation by Binding Proexosite 1 on Prothrombin.

Colin A. Kretz, BSc, Alan R. Stafford, MSc, James C. Fredenburgh, PhD, Jeffrey I. Weitz, MD

Blood (2005) 106 (11): 1950.

https://doi.org/10.1182/blood.V106.11.1950.1950

Published: 2005

Journal Articles

Zinc 2+ Promotes Heparin Binding to Fibrin and Subsequent Formation of Ternary Heparin-Thrombin-Fibrin Complexes.

Beverly A. Leslie, BSc, Alan R. Stafford, MSc, James C. Fredenburgh, PhD, Jeffrey I. Weitz, MD

Blood (2005) 106 (11): 1956.

https://doi.org/10.1182/blood.V106.11.1956.1956

Published: 2005

Journal Articles

No Fibrinolytic Benefit of Adjunctive Anticoagulation during Arterial Thrombolysis Induced by tPA Combined with TAFIa Inhibitor in a Rabbit Arterial Thrombosis Model.

Petr Klement, DVM, PhD, Peng Liao, MD, MA, Frank Chen, MD, Jeffrey I. Weitz, MD

Blood (2004) 104 (11): 2979.

https://doi.org/10.1182/blood.V104.11.2979.2979

Published: 2004

Journal Articles

Role of Plasminogen-Fibrin Interaction in Plasminogen Activation by t-PA.

Long D. Tieu, BSc, Jim C. Fredenburgh, PhD, Alan R. Stafford, MSc, Jeffrey I. Weitz, MD.

Blood (2004) 104 (11): 1737.

https://doi.org/10.1182/blood.V104.11.1737.1737

Published: 2004

Journal Articles

Role of Thrombin Exosites in Protection from Inhibition by Antithrombin in the Presence of Heparin and Fibrin.

James C. Fredenburgh, PhD, Alan R. Stafford, MSc, Jeffrey I. Weitz, MD

Blood (2004) 104 (11): 1721.

https://doi.org/10.1182/blood.V104.11.1721.1721

Published: 2004

NARROW

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial

Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism

Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients

Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism

Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty.

Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation

Thrombin Aptamer HD1 Inhibits Prothrombin Activation by Binding Proexosite 1 on Prothrombin.

Zinc 2+ Promotes Heparin Binding to Fibrin and Subsequent Formation of Ternary Heparin-Thrombin-Fibrin Complexes.

No Fibrinolytic Benefit of Adjunctive Anticoagulation during Arterial Thrombolysis Induced by tPA Combined with TAFIa Inhibitor in a Rabbit Arterial Thrombosis Model.

Role of Plasminogen-Fibrin Interaction in Plasminogen Activation by t-PA.

Role of Thrombin Exosites in Protection from Inhibition by Antithrombin in the Presence of Heparin and Fibrin.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only